Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONNEX-2 phase III trial of iclepertin in schizophrenia
2020-003744-84Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2021
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Iclepertin with Placebo (2 arms). Primary endpoint: Change from baseline in overall composite T-score of the MCCB after 26 weeks of treatment. Started Mar 2021; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2020-003744-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003744-84.